Evaluation of the efficacy of a melatoninergic antidepressant in patients with epilepsy and comorbid mood disorders and sleep disorders
Authors
V.A. Mikhailov
N.A. Sivakova
N.I. Shova
O.N. Yakunina
I.V. Abramova
Federal State Budgetary Institution “V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology” of the Ministry of Health of the Russian Federation, St. Petersburg, Russian Federation
https://doi.org/10.26617/1810-3111-2026-3(132)-60-69
Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2026; 3 (132): 60-69.
Abstract
Background. Mood disorders, anxiety disorders, and sleep disorders are among the most common comorbid psychopathological conditions in epilepsy; they significantly affect patients’ quality of life, adherence to antiepileptic therapy, social functioning, and the overall prognosis of the disease. Melatoninergic antidepressants can be clinically effective in patients presenting with a combination of depressive-anxious symptoms and insomnia. However, data regarding their use in patients with epilepsy remain limited. Objective. To evaluate changes in affective symptoms, sleep quality, and clinical safety parameters in patients with epilepsy, comorbid mood disorders, and insomnia during 12 weeks of agomelatine therapy. Material and Methods. A single-site, prospective, open-label study was conducted involving 30 adult patients with epilepsy, mood disorders, and insomnia. Agomelatine was prescribed at a dose of 25 mg at bedtime, with a possible increase to 50 mg after 2 weeks if clinical improvement was insufficient. Assessments included the Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI) scale, seizure frequency, adverse events, and electroencephalography (EEG) data. Results.After 12 weeks, a reduction in anxiety severity was observed on the HADS (from 9.67±1.83 to 7.63±1.85 points) and depression severity (from 8.83±1.74 to 6.53±2.05 points), as well as a decrease in depression severity on the BDI (from 21.23±4.59 to 11.50±4.47 points). The Pittsburgh Sleep Quality Index score decreased from 14.93 ± 5.19 to 7.67 ± 2.41 points. Daytime sleepiness, as measured by the Epworth Sleepiness Scale, also decreased; however, the clinical significance of this change requires cautious interpretation. Condition severity, assessed via the Clinical Global Impression scale, dropped from 3.77 ± 0.86 to 1.73 ± 0.69 points. No significant adverse changes were observed in electroencephalography data. Conclusion. In this open-label study, the administration of agomelatine as an adjunct to baseline therapy in patients with epilepsy, comorbid mood disorders, and insomnia was associated with reduced anxiety-depressive symptoms and improved subjective sleep quality, with a satisfactory tolerability profile. These findings require confirmation in larger, placebo-controlled trials.
Keywords: epilepsy, affective disorders, depression, anxiety, insomnia, melatoninergic antidepressants, agomelatine, electroencephalography.
Contacts
This email address is being protected from spambots. You need JavaScript enabled to view it.
Materials
For citation: Mikhailov V.A., Sivakova N.A., Shova N.I., Yakunina O.N., Abramova I.V. Evaluation of the efficacy of a melatoninergic antidepressant in patients with epilepsy and comorbid mood disorders and sleep disorders. Siberian Herald of Psychiatry and Addiction Psychiatry.2026; 3 (132): 60-69. https://doi.org/10.26617/1810-3111-2026-3(132)-60-69
REFERENCES
- Giussani G, Bianchi E, Beretta S et al. Comorbidities in patients with epilepsy: Frequency, mechanisms and effects on long-term outcome. Epilepsia. 2021October; 62(10):2395-2404. https://doi.org/10.1111/epi.17022.
- Jiang T, Zhang X, Zhang M et al. Drug-resistant idiopathic generalized epilepsy: A meta-analysis of prevalence and risk factors. Epilepsy Behavior. 2023JSeptember; 146:109364.https://doi.org/10.1016/j.yebeh.2023.109364.
- Kanner AM, Saporta AS, Kim DH, et al. Mood and anxiety disorders and suicidality in patients with newly diagnosed focal epilepsy: An analysis of a complex comorbidity. Neurology. 2023 March 14;100(11):e1123-e1134. https://doi.org/ 10.1212/WNL.0000000000201671. Epub 2022 December 20. Erratum in: Neurology. 2025 October21;105(8):e213520. https://doi.org/ 10.1212/WNL.0000000000213520. PMID: 36539302; PMCID: PMC10074468.
- GonçalvesEB, de Oliveira Cardoso TAM, Yasuda CL, Cendes F. Depressive disorders in patients with pharmaco-resistant mesial temporal lobe epilepsy. J Int Med Res. 2018; 46(2):752-760. https://doi.org/10.1177/0300060517717825.
- Nogueira MH, Yasuda CL, Coan AC, Kanner AM, Cendes F. Concurrent mood and anxiety disorders are associated with pharmacoresistant seizures in patients with MTLE. Epilepsia. 2017May;58(Suppl. 46):1268-1276. https://doi.org/10.1111/epi.13781.
- Karlov VA, Inozemtseva OS, Novoselova GB. Sleep disorders in epileptic patients. Epilepsy and Paroxysmal Conditions. 2017;9(1):36-39. https://doi.org/10.17749/2077-8333.2017.9.1.036-039 (in Russian).
- Gutter T, Callenbach PMC, Brouwer OF, de Weerd AW. Prevalence of sleep disturbances in people with epilepsy and the impact on quality of life. Seizure. 2019July;69:298-303.https://doi.org/10.1016/j.seizure.2019.04.019.
- Im HJ, Park SH, Baek SH, Chu MK, Yang KI, Kim WJ, Yun CH. Associations of impaired sleep quality, insomnia, and sleepiness with epilepsy: A questionnaire-based case-control study. Epilepsy Behav. 2016 April;57(Pt A):55-59.https://doi.org/10.1016/j.yebeh.2016.01.022. Epub 2016 Feb 26. PMID: 26921599.
- Bergmann M, Prieschl M, Stefani A et al. A prospective controlled study about sleep disorders in drug resistant epilepsy. Sleep Med. 2020 September;75:434-440.https://doi.org/10.1016/j.sleep.2020.09.001.
- Peter-Derex L, Klimes P, Latreille V, Bouhadoun S, Dubeau F, Frauscher B. Sleep disruption in epilepsy: Ictal and interictal epileptic activity matter. Annals of Neurology. 2020 September;88(5): 907-920. https://doi.org/10.1002/ana.25884.
- Mikhailov VA, Sivakova NA, Guseva MV. Affective and conversion (dissociative) disorders in patients with epilepsy. Attending Physician. 2025;28(11):36-42. https://doi.org/10.51793/OS.2025.28.11.004(in Russian).
- Kanner AM, Saporta AS, Kim DH et al. Mood and anxiety disorders and suicidality in patients with newly diagnosed focal epilepsy: An analysis of a complex comorbidity. Neurology. 2023 March 14;100(11):e1123-e1134. https://doi.org/ 10.1212/WNL.0000000000201671. Epub 2022 December 20. Erratum in: Neurology. 2025 October21;105(8):e213520.https://doi.org/10.1212/WNL.0000000000213520. PMID: 36539302; PMCID: PMC10074468.
- Jacoby A, Snape D, Lane S, Baker GA. Self-reported anxiety and sleep problems in people with epilepsy and their association with quality of life. Epilepsy Behav. 2015 February;43:149-58. https://doi.org/10.1016/j.yebeh.2014.09.071. Epub 2015 January16. PMID: 25599986.
- Shen Y, Zhang M, Wang Y et al. Subjective sleep disturbance in Chinese adults with epilepsy: Associations with affective symptoms. Epilepsy Research. 2017 July; 135:150-157. https://doi.org/10.1016/j.eplepsyres.2017.06.014.
- Staniszewska A, Mąka A, Religioni U, Olejniczak D. Sleep disturbances among patients with epilepsy. Neuropsychiatr Dis Treat. 2017 July10;13:1797-1803. https://doi.org/ 10.2147/NDT.S136868. PMID: 28744129; PMCID: PMC5513823.
- Planas-Ballvé A, Grau-López L, Jiménez M, Ciurans J, Fumanal A, Becerra J. Insomnia and poor sleep quality are associated with poor seizure control in patients with epilepsy. Neurologia. 2022; 37:639-46. https://doi.org/10.1016/j.nrleng.2019.07.008.
- Moser D, Pablik E, Aull-Watschinger S et al. Depressive symptoms predict the quality of sleep in patients with partial epilepsy: A combined retrospective and prospective study. Epilepsy & Behavior. 2015; 47:104-110.https://doi.org/10.1016/j.yebeh.2015.04.021.